8H0.F PolyPeptide Group AG

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
43.60 EUR
Close of Nov 11, 2026
25.60 53.00
Market cap
EUR 1.44B
P/E
99.1x
P/B
4.08x
ROE
-6.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 8H0.F undervalued?

Graham number

The Graham number of PolyPeptide Group AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PolyPeptide Group AG fundamental analysis

No fundamental analysis for PolyPeptide Group AG yet.

PolyPeptide Group AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as wel…

Full company profile